Results 141 to 150 of about 241,274 (262)

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

open access: yesAdvanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou   +12 more
wiley   +1 more source

An introduction to anticancer drugs

open access: yes, 2012
An introduction to anticancer drugs\ud 24.1 Introduction\ud 24.2 The rationale behind anticancer drug therapy\ud 24.3 Drugs used in cancer\ud 24.3.1 Alkylating agents\ud 24.3.2 Cytotoxic antibiotics\ud 24.3.3 Antimetabolites\ud 24.3.4 Microtubule ...
Mullaney, Ian
core  

Carboranyl‐Curcuminoids for the Neutron Capture‐Based Treatment of Amyloid Aggregates in Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
The 10B‐enriched monocarbonyl analog of curcumin (BMAC) 10B‐9 enables site‐specific Boron Neutron Capture Therapy (BNCT) on amyloid‐β (Aβ) fibrils. Neutron irradiation induces histidine oxidation and fibril destabilization, as revealed by 1H‐NMR and FESEM analyses.
Sebastiano Micocci   +13 more
wiley   +1 more source

Anticancer agents and use

open access: yes, 2006
Provided herein are compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl groups, also referred to as ...
Dang, Yongjun   +6 more
core  

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

open access: yesAdvanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun   +15 more
wiley   +1 more source

Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?

open access: yes, 2008
Protein kinase CK2 is a ubiquitous, essential, and highly pleiotropic protein kinase whose abnormally high constitutive activity is suspected to underlie its pathogenic potential in neoplasia and other diseases.
COZZA, GIORGIO   +2 more
core  

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

Light‐Activatable Nitric Oxide Release via Intramolecular Electron Transfer for Tumor Pyroptosis Induction

open access: yesAdvanced Science, EarlyView.
This work proposes a novel strategy to fabricate unimolecular pyroptosis photoinitiators activated by deep‐red light at low light doses. It relies on a photosensitization mechanism to trigger nitric oxide (NO) release from benzisothiadiazole‐based N‐nitrosanilines without modification of nitro moieties, thereby boosting pyroptosis‐mediated ...
Chuangxin Zhang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy